STOCK TITAN

[Form 4] Chemours Co Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4

Chemours director Satterthwaite Livingston received 966 deferred stock units on 09/30/2025, each equal to one share of Chemours common stock and recorded at an acquisition price of $15.84 per unit. After the transaction the reporting person beneficially owns 3,280.0507 shares (direct). The deferred stock units become payable beginning the second calendar year after the reporting person ceases service as a director, so these units represent compensation that vests for payout on termination rather than immediate cash or share delivery. The Form 4 was signed by an attorney-in-fact on 10/02/2025 and identifies the reporting person as a director of Chemours (ticker: CC).

Il direttore di Chemours Satterthwaite Livingston ha ricevuto 966 unità di azioni differite il 30/09/2025, ciascuna equivalente a una azione ordinaria di Chemours e registrata a un prezzo di acquisizione di 15,84$ per unità. Dopo la transazione la persona che riporta beneficia possiede 3.280,0507 azioni (dirette). Le unità azionarie differite diventano pagabili a partire dal secondo anno solare successivo alla cessazione della carica di direttore, quindi queste unità rappresentano una retribuzione che matura per liquidazione al termine del servizio anziché una consegna immediata di denaro o azioni. Il Form 4 è stato firmato da un procuratore-in-fact il 02/10/2025 e identifica la persona che riporta come direttore di Chemours (ticker: CC).

El director de Chemours, Satterthwaite Livingston, recibió 966 unidades diferidas de acciones el 30/09/2025, cada una equivalente a una acción ordinaria de Chemours y registradas a un precio de adquisición de 15,84$ por unidad. Tras la transacción, la persona reportante posee beneficiosamente 3.280,0507 acciones (directas). Las unidades de acciones diferidas pasan a ser pagaderas a partir del segundo año calendario después de que la persona reportante cese su cargo como director, por lo que estas unidades representan una compensación que se consolida para el pago al finalizar el mandato, en lugar de entrega inmediata de dinero o acciones. El Formulario 4 fue firmado por un apoderado en el acto el 02/10/2025 e identifica a la persona reportante como director de Chemours (ticker: CC).

Chemours 이사 Satterthwaite Livingston은 2025년 9월 30일 966주의 이연 주식 단위를 받았으며, 각 단위는 Chemours 보통주 한 주에 해당하고 단위당 취득가가 15.84달러로 기록되었습니다. 거래 후 보고자는 3,280.0507주의 직접 보유지분을 소유합니다. 이연 주식 단위는 보고자가 이사로서 서비스 종료 후 두 번째 달력 연도부터 지급 가능한 형태가 되므로, 이들 단위는 즉시 현금이나 주식 배당이 아닌 종료 시 지급될 보상을 나타냅니다. Form 4는 2025년 10월 2일에 대리인이 서명했고, 보고자를 Chemours의 이사로 식별합니다(종목 기호: CC).

Le directeur de Chemours, Satterthwaite Livingston, a reçu 966 unités d’actions différées le 30/09/2025, chacune équivalant à une action ordinaire de Chemours et enregistrée à un prix d’acquisition de 15,84 $ par unité. Après la transaction, la personne déclarant détient 3 280,0507 actions (directes). Les unités d’actions différées deviennent exigibles à partir de la deuxième année civile après la fin du mandat du directeur, de sorte que ces unités représentent une compensation qui se vÃt pour liquidation lors de la cessation de service, plutôt qu’une remise immédiate d’argent ou d’actions. Le Formulaire 4 a été signé par un mandataire le 02/10/2025 et identifie la personne déclarante comme directeur de Chemours (ticker : CC).

Chemours-Direktor Satterthwaite Livingston erhielt am 30.09.2025 966 aufgeschobene Aktieneinheiten, von denen jede einer Stammaktie von Chemours entspricht und mit einem Erwerbspreis von 15,84 $ pro Einheit verzeichnet ist. Nach der Transaktion besitzt die meldepflichtige Person 3.280,0507 Aktien (direkt). Die aufgeschobenen Aktieneinheiten werden ab dem zweiten Kalendertag nach dem Ausscheiden der Person als Direktor zahlbar, sodass diese Einheiten eine Vergütung darstellen, die bei Beendigung der Tätigkeit ausgezahlt wird, statt sofort Bargeld oder Aktien zu liefern. Das Formular 4 wurde von einem Bevollmächtigten am 02.10.2025 unterschrieben und identifiziert die meldende Person als Direktor von Chemours (Ticker: CC).

تلقى مدير Chemours Satterthwaite Livingston 966 وحدة أسهم مؤجلة في 30/09/2025، وكل وحدة تساوي سهماً واحداً من أسهم Chemours العادية ومسجلة بسعر اكتساب قدره 15.84 دولارًا للوحدة. بعد الصفقة، يمتلك الشخص المبلغ عنه بشكل مستفيد 3,280.0507 أسهم (مباشر). تصبح وحدات الأسهم المؤجلة قابلة للدفع بدءاً من السنة التقويمية الثانية بعد انتهاء خدمة الشخص كمدير، لذا فإن هذه الوحدات تمثل تعويضاً يتم صرفه عند إنهاء الخدمة وليس تسليمًا نقديًا فوريًا أو أسهماً. تم توقيع النموذج 4 من قبل وكيل في التاريخ 02/10/2025 ويحدد الشخص المبلغ عنه كمدير لشركة Chemours (الرمز: CC).

Chemours 董事 Satterthwaite Livingston 于 2025-09-30 收到 966 单位递延股票,每单位等于 Chemours 普通股一股,按每单位 15.84 美元的获取价格记入。 交易后,申报人实际拥有 3,280.0507 股(直接持有)。递延股票单位在报告人停止担任董事后的第二个日历年开始可支付,因此这些单位代表在终止任职时才支付的报酬,而不是即时的现金或股票交割。Form 4 于 2025-10-02 由代理签署,且将申报人列为 Chemours 的董事(股票代码:CC)。

Positive
  • Transparency: The Form 4 discloses the number of deferred stock units, acquisition date, and price ($15.84), providing clear record of insider holdings.
  • Alignment with shareholders: Deferred stock units tie director compensation to share value and are payable after service ends, aligning long-term interests.
Negative
  • None.

Insights

TL;DR: Routine director compensation recorded as 966 deferred stock units; modest change in beneficial ownership.

Receipts of 966 deferred stock units at $15.84 each are typical non-cash director compensation that increase reported beneficial ownership to 3,280.0507 shares. This transaction does not show an immediate cash sale or purchase of common stock and represents deferred equity exposure tied to future termination timing. For investors, the item is informative about director compensation structure but is not a material change to capital structure based solely on the numbers reported.

TL;DR: Standard deferred equity grant for a director; payout contingent on post-termination timing.

The filing documents a deferred stock unit award where each unit equals one share and becomes payable beginning in the second calendar year after the director leaves service. That design is consistent with deferred compensation practices intended to align long-term interests without immediate dilution. The Form 4 clearly states the nature and payout timing, providing transparency on insider holdings and compensation timing.

Il direttore di Chemours Satterthwaite Livingston ha ricevuto 966 unità di azioni differite il 30/09/2025, ciascuna equivalente a una azione ordinaria di Chemours e registrata a un prezzo di acquisizione di 15,84$ per unità. Dopo la transazione la persona che riporta beneficia possiede 3.280,0507 azioni (dirette). Le unità azionarie differite diventano pagabili a partire dal secondo anno solare successivo alla cessazione della carica di direttore, quindi queste unità rappresentano una retribuzione che matura per liquidazione al termine del servizio anziché una consegna immediata di denaro o azioni. Il Form 4 è stato firmato da un procuratore-in-fact il 02/10/2025 e identifica la persona che riporta come direttore di Chemours (ticker: CC).

El director de Chemours, Satterthwaite Livingston, recibió 966 unidades diferidas de acciones el 30/09/2025, cada una equivalente a una acción ordinaria de Chemours y registradas a un precio de adquisición de 15,84$ por unidad. Tras la transacción, la persona reportante posee beneficiosamente 3.280,0507 acciones (directas). Las unidades de acciones diferidas pasan a ser pagaderas a partir del segundo año calendario después de que la persona reportante cese su cargo como director, por lo que estas unidades representan una compensación que se consolida para el pago al finalizar el mandato, en lugar de entrega inmediata de dinero o acciones. El Formulario 4 fue firmado por un apoderado en el acto el 02/10/2025 e identifica a la persona reportante como director de Chemours (ticker: CC).

Chemours 이사 Satterthwaite Livingston은 2025년 9월 30일 966주의 이연 주식 단위를 받았으며, 각 단위는 Chemours 보통주 한 주에 해당하고 단위당 취득가가 15.84달러로 기록되었습니다. 거래 후 보고자는 3,280.0507주의 직접 보유지분을 소유합니다. 이연 주식 단위는 보고자가 이사로서 서비스 종료 후 두 번째 달력 연도부터 지급 가능한 형태가 되므로, 이들 단위는 즉시 현금이나 주식 배당이 아닌 종료 시 지급될 보상을 나타냅니다. Form 4는 2025년 10월 2일에 대리인이 서명했고, 보고자를 Chemours의 이사로 식별합니다(종목 기호: CC).

Le directeur de Chemours, Satterthwaite Livingston, a reçu 966 unités d’actions différées le 30/09/2025, chacune équivalant à une action ordinaire de Chemours et enregistrée à un prix d’acquisition de 15,84 $ par unité. Après la transaction, la personne déclarant détient 3 280,0507 actions (directes). Les unités d’actions différées deviennent exigibles à partir de la deuxième année civile après la fin du mandat du directeur, de sorte que ces unités représentent une compensation qui se vÃt pour liquidation lors de la cessation de service, plutôt qu’une remise immédiate d’argent ou d’actions. Le Formulaire 4 a été signé par un mandataire le 02/10/2025 et identifie la personne déclarante comme directeur de Chemours (ticker : CC).

Chemours-Direktor Satterthwaite Livingston erhielt am 30.09.2025 966 aufgeschobene Aktieneinheiten, von denen jede einer Stammaktie von Chemours entspricht und mit einem Erwerbspreis von 15,84 $ pro Einheit verzeichnet ist. Nach der Transaktion besitzt die meldepflichtige Person 3.280,0507 Aktien (direkt). Die aufgeschobenen Aktieneinheiten werden ab dem zweiten Kalendertag nach dem Ausscheiden der Person als Direktor zahlbar, sodass diese Einheiten eine Vergütung darstellen, die bei Beendigung der Tätigkeit ausgezahlt wird, statt sofort Bargeld oder Aktien zu liefern. Das Formular 4 wurde von einem Bevollmächtigten am 02.10.2025 unterschrieben und identifiziert die meldende Person als Direktor von Chemours (Ticker: CC).

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
1. Name and Address of Reporting Person*
SATTERTHWAITE LIVINGSTON

(Last) (First) (Middle)
C/O THE CHEMOURS COMPANY
1007 MARKET STREET

(Street)
WILMINGTON DE 19801

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Chemours Co [ CC ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
09/30/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Deferred Stock Units (1) 09/30/2025 A 966 (1) (1) Common Stock 966 $15.84 3,280.0507 D
Explanation of Responses:
1. Each deferred stock unit is the economic equivalent of one share of the Issuer's common stock. The deferred stock units become payable upon the second calendar year following the Reporting Person's termination of service as a director.
/s/ Eric Stein, Attorney-in-Fact 10/02/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Chemours director Satterthwaite Livingston acquire on 09/30/2025?

The reporting person received 966 deferred stock units, each equivalent to one share of Chemours common stock.

How many shares does Livingston beneficially own after the reported transaction?

Following the transaction the reporting person beneficially owns 3,280.0507 shares (direct).

When are the deferred stock units payable?

The deferred stock units become payable beginning the second calendar year after the reporting person’s termination of service as a director.

What price is recorded for the deferred stock units on the Form 4?

The Form 4 lists a price of $15.84 per deferred stock unit.

Who signed the Form 4 and when?

The Form 4 was signed by Eric Stein, Attorney-in-Fact on 10/02/2025.
Chemours Co

NYSE:CC

CC Rankings

CC Latest News

CC Latest SEC Filings

CC Stock Data

2.37B
148.93M
0.46%
101.19%
10.03%
Specialty Chemicals
Chemicals & Allied Products
Link
United States
WILMINGTON